One-year clinical outcome of a randomized trial of polymer-free paclitaxel-eluting stents versus biodegradable polymer-based rapamycin-eluting stents in patients with coronary heart disease

Journal of Interventional Cardiology

Volumn 25, Issue 6, 2012, Pages 604-610

  Zhang, Lan ^a   Yuan, Jia ^a   Liu, Gan ^a   Zhong, Jin Peng ^a   Yin, Yue Hui ^a   She, Qiang ^a   Su, Li ^a   Ling, Zhi Yu ^a   Chen, Yun Qing ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; ENOXAPARIN; HEPARIN; NADROPARIN; PACLITAXEL; POLYMER; RAPAMYCIN;

ADULT; AGED; ARTICLE; BIODEGRADABLE IMPLANT; CONTROLLED STUDY; CORONARY STENT; DRUG ELUTING STENT; FEMALE; HEART DISEASE; HOSPITAL READMISSION; HUMAN; ISCHEMIC HEART DISEASE; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STENT THROMBOSIS;

ABSORBABLE IMPLANTS; AGED; ANGIOPLASTY, BALLOON, CORONARY; CARDIOVASCULAR AGENTS; CORONARY ARTERY DISEASE; DRUG-ELUTING STENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; PACLITAXEL; PATIENT READMISSION; POLYMERS; SIROLIMUS; THROMBOSIS;

EID: 84871306759     PISSN: 08964327     EISSN: 15408183     Source Type: Journal    
DOI: 10.1111/j.1540-8183.2012.00722.x     Document Type: Article

References (25)

1. Stone GW, Ellis SG, Cannon L, et al,. Comparison of a polymer based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: A randomized controlled trial. JAMA 2005; 294: 1215-1223.
2. Pfisterer M, Brunner-La Rocca HP, Buser PT, et al,. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: An observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 2006; 48: 2584-2591.
3. Wessely R, Hausleiter J, Michaelis C, et al,. Inhibition of neointima formation by a novel drug-eluting stent system that allows for dose adjustable, multiple, and on-site stent coating. Arterioscler Thromb Vasc Biol 2005; 25: 748-753.
4. Buszman P, Trznadel S, Milewski K, et al,. Novel paclitaxel-eluting, biodegradable polymer coated stent in the treatment of de novo coronary lesions: A prospective multicenter registry. Catheter Cardiovasc Interv 2008; 71: 51-57.
5. Mehilli J, Kastrati A, Wessely R, et al,. Randomized trial of a nonpolymer-based rapamycin-eluting stent versus a polymer-based paclitaxel-eluting stent for the reduction of late lumen loss. Circulation 2006; 113: 273-279.
6. Byrne RA, Kastrati A, Kufner S, et al,. Randomized, non-inferiority trial of three limus agent-eluting stents with different polymercoatings: The Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial. Eur Heart J 2009; 30: 2441-2449.
7. Serruys PW, Daemen J,. Are drug-eluting stents associated with a higher rate of late thrombosis than bare metal stents? Late stent thrombosis: A nuisance in both bare metal and drug-eluting stents. Circulation 2007; 115: 1433-1439.
8. Han Y, Jing Q, Chen X, et al., Long-term clinical, angiographic, and intravascular ultrasound outcomes of biodegradable polymer-coated sirolimus-eluting stents. Catheter Cardiovasc Interv 2008; 72: 177-183.
9. Zheng QS, Sun RY, Chen ZY,. Sample size estimation and equivalence margin in noninferiority and equivalence trials (Chinese). Chin J New Drugs 2003; 12: 368-371.
10. Liu Y, Yao C, Chen F, et al,. Statistical issues in noninferiority/ equivalence trial (Chinese). Chin J Clin Pharmacol 2000; 16: 448-452
11. Maisel WH,. Unanswered questions-drug eluting stents and the risk for stent thrombosis. N Engl J Med 2007; 356: 981-984.
12. Lagerqvist B, James SK, Stenestrand U, et al., SCAAR Study Group. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 2007; 356: 1009-1019.
13. Schofer J, Schlüter M, Gershlick AH, et al,. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: Double-blind, randomised controlled trial (E-SIRIUS). Lancet 2003; 362: 1093-1099.
14. Grube E, Silber S, Hauptmann KE, et al,. TAXUS I: Six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation 2003; 107: 38-42.
15. Tanabe K, Serruys PW, Grube E, et al,. TAXUS III Trial: In-stent restenosis treated with stent based delivery of paclitaxel incorporated in a slow-release polymer formulation. Circulation 2003; 107: 559-564.
16. Lemos PA, Serruys PW, van Domburg RT, et al,. Unrestricted utilization of Rapamycin-eluting stents compared with conventional bare stent implantation in the "real world": The Rapamycin-eluting stent evaluated at rotterdan cardiology hospital (RESEARCH) registry. Circulation 2004; 109: 190-193.
17. Tanabe K, Serruys PW, Degertekin M, et al,. Chronic arterial responses to polymer-controlled paclitaxel-eluting stents: Comparison with bare metal stents by serial intravascular ultrasound analyses: Data from the randomized TAXUS-II trial. Circulation 2004; 109: 196-200.
18. Schampaert E, Cohen EA, Schlüter M, et al,. The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol 2004; 43: 1110-1115.
19. Stone GW, Ellis SG, Cox DA, et al,. One-year clinical results with the slow-release polymer-based, paclitaxel-eluting TAXUS stent: The TAXUS-IV trial. Circulation 2004; 109: 1942-1947.
20. Lim SY, Jeong MH, Hong SJ, et al,. Inflammation and delayed endothelization with overlapping drug-eluting stents in a porcine model of in-stent restenosis. Circ J 2008; 72: 463-468.
21. Joner M, Finn AV, Farb A, et al,. Pathology of drug-eluting stents in humans: Delayed healing and late thrombotic risk. J Am Coll Cardiol 2006; 48: 193-202.
22. Virmani R, Guagliumi G, Farb A, et al,. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: Should we be cautious? Circulation 2004; 109: 701-705.
23. Han Y, Jing Q, Xu B, et al,. Safety and efficacy of biodegradable polymer-coated Rapamycin-eluting stents in "real-world" practice: 18-month clinical and 9-month angiographic outcomes. JACC Cardiovasc Interv 2009; 2: 310-311.
24. Mehilli J, Byrne RA, Wieczorek A, et al,. Randomized trial of three Rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis. Eur Heart J 2008; 29: 1975-1982.
25. Byrne RA, Kastrati A, Tiroch K, et al,. 2-year clinical and angiographic outcomes from a randomized trial of polymer-free dual drug-eluting stents versus polymer-based Cypher and Endeavor, drug-eluting stents. J Am Coll Cardiol 2010; 55: 2536-2543.